Niche Diagnostics to Support Precision Treatment for Every Cancer Patient

Translate:

What is Precision Cancer Treatment ?

Precision Medicine in Cancer Treatment

Precision medicine is an approach to patient care that allows doctors to select treatments that are most likely to help patients based on a genetic understanding of their disease.

Changes that occur in one person’s cancer may not occur in others who have the same type of cancer.

The same cancer-causing changes may be found in different types of cancer.

To be eligible for precision medicine, your tumor must be tested for genetic change that can be targeted by a treatment currently available in the market or in Clinical Trials.

See List of FDA Approved Drugs.

Find out more

How Genetic Changes in Your Cancer Are Identified

To figure out which genetic changes are in your cancer, you may need to have a biopsy.

A biopsy is a procedure in which your doctor removes a sample of the cancer.

Your sample will be sent to the Star Biosciences Lab, where a machine called a DNA sequencer looks for genetic changes that may be causing the cancer to grow.

The process of looking for genetic changes in cancer may be called DNA sequencing, genomic testing, molecular profiling, or tumor profiling.

Find out more

Discuss Precision Medicine Options with your Oncologist

Contact Star Biosciences to Begin your Precision Treatment Journey

Contact Star Biosciences

Repertoire of Precision Tests to Detect Cancer Biomarkers

Immuno - Oncology

Immuno-Oncology (I-O) is the investigation of innovative approaches that aim to harness the body’s natural immune response to fight cancer.

Immuno-Oncology testing helps determine which patients are good candidates for immunotherapy. Star Bioscience Laboratories is a leader in precision diagnostics and is at the forefront of immunotherapy testing.

Tumor Mutation Burden (TMB): This genomic biomarker is designed to predict response to checkpoint inhibitor immunotherapies targeting the PD-1 and PD-L1 proteins. Studies in lung, melanoma and bladder cancers showed that objective response to checkpoint immunotherapy was predicted by the presence of high TMB.

Microsatellite Instability (MSI) and Mismatch Repair (MMR): KEYTRUDA® was approved by the FDA for the treatment of certain patients with metastatic solid tumors that have been identified as being MSI-high or mismatch repair deficient (dMMR)1. OPDIVO® is FDA-approved for certain colorectal cancer patients with MSI-high or dMMR2.

PD-L1: This immunohistochemical assay detects the level and expression sites of PD-L1 protein. As a companion or complementary diagnostic for certain tumors and indications, it helps identify patients for treatments including KEYTRUDA, OPDIVO, TECENTRIQ® and IMFINZI™.

Review our Tests

Liquid Biopsy

Its a "Blood Test". It helps your doctor identify whether your treatment is working and pinpoints the status of your disease progression. Tests are highly specific for Lung, Breast, Colon and Prostate Cancers. Test results are delivered within 5 days.

Our Liquid Biopsy services can assist our patients in:

Performing tumor profiling
Surveillance of tumors and their response to therapy
Monitor heterogeneity
Testing for minimal residual disease (MRD)
Helping predict early relapse

Testing using liquid biopsies is more sensitive than other diagnostic testing methods like bone marrow taps, which are invasive and painful for patients.

Review our Tests

Multi - Gene Testing

Targeted therapy is a newer type of cancer treatment that uses drugs or other substances to more precisely identify and attack cancer cells. Targeted therapy is a growing part of the treatment for many types of cancer.

Multi-Gene testing helps your doctor identify drugs that work against the "Genetic Defect" causing your Cancer. These tests are performed on "All Cancer Types" and help Personalize your Treatment.

Cancer Specific tests:

Star Biosciences brings breadth and depth of service to support oncologists in making diagnoses, assessing prognoses, and discovering opportunities for targeted therapy in their patients with solid tumors.

Review our Tests

FDA Approved Precision Drugs for Cancer

DRUGS FOR SOLID TUMORS

Ado-trastuzumab emtansine (Kadcyla)

Target: HER2 (ERBB2/neu)
FDA Approved Indication:
- Breast cancer (HER2+)

Afatinib (Gilotrif)

Target: EGFR (HER1/ERBB1), HER2 (ERBB2/neu)
FDA Approved Indication:
- Non-small cell lung cancer (with EGFR exon 19 deletions or exon 21 substitution (L858R) mutations)

Aldesleukin (Proleukin)

FDA Approved Indication:
- Renal cell carcinoma
- Melanoma.

Alectinib (Alecensa)

Target: ALK
FDA Approved Indication:
- Non-small cell lung cancer (with ALK fusion)

Atezolizumab (Tecentriq)

Target: PD-L1
FDA Approved Indication:
- Urothelial carcinoma
- Non-small cell lung cancer

Avelumab (Bavencio)

Target: PD-L1
FDA Approved Indication:
- Merkel cell carcinoma
- Urothelial cancer

Axitinib (Inlyta)

Target: KIT, PDGFRβ, VEGFR1/2/3
FDA Approved Indication:
- Renal cell carcinoma

Belimumab (Benlysta)

Target: BAFF
FDA Approved Indication:
- Lupus erythematosus

Bevacizumab (Avastin)

Target: VEGF ligand
FDA Approved Indications:
- Cervical cancer
- Colorectal cancer
- Fallopian tube cancer
- Glioblastoma
- Non-small cell lung cancer
- Ovarian cancer
- Peritoneal cancer
- Renal cell carcinoma

Bosutinib (Bosulif)

Target: ABL
FDA Approved Indication:
- Chronic myelogenous leukemia (Philadelphia chromosomepositive)

Brigatinib (Alunbrig)

Target:ALK
FDA Approved Indication:
- Non-small cell lung cancer (ALK+)

Cabozantinib (Cabometyx [tablet], Cometriq [capsule])

Target: FLT3, KIT, MET, RET, VEGFR2
FDA Approved Indication:
- Medullary thyroid cancer
- Renal cell carcinoma

Ceritinib (Zykadia)

Target: ALK
FDA Approved Indication:
- Non-small cell lung cancer (with ALK fusion)

Cetuximab (Erbitux)

Target: EGFR (HER1/ERBB1)
FDA Approved Indication:
- Colorectal cancer (KRAS wild type),
- Squamous cell cancer of the head and neck

Cobimetinib (Cotellic)

Target: MEK
FDA Approved Indication:
- Melanoma (with BRAF V600E or V600K mutation)

Crizotinib (Xalkori)

Target: ALK, MET, ROS1
FDA Approved Indication:
- Non-small cell lung cancer (with ALK fusion or ROS1 genealteration)

Dabrafenib (Tafinlar)

Target: BRAF
FDA Approved Indication:
- Melanoma (with BRAF V600 mutation)
- Non-small cell lung cancer (with BRAF V600E mutation)

Denosumab (Xgeva)

Target: RANKL
FDA Approved Indication:
- Giant cell tumor of the bone

Dinutuximab (Unituxin)

Target: B4GALNT1 (GD2)
FDA Approved Indication: Pediatric neuroblastoma

Durvalumab (Imfinzi)

Target: PD-L1
FDA Approved Indication:
- Urothelial carcinoma
- Non-small cell lung cancer

Enasidenib (Idhifa)

Target: IDH2
FDA Approved Indication:
- Acute myeloid leukemia (with IDH2 mutation)

Erlotinib (Tarceva)

Target: EGFR (HER1/ERBB1)
FDA Approved Indication:
- Non-small cell lung cancer (with EGFR exon 19 deletions or exon 21 substitution (L858R) mutations)
- Pancreatic cancer

Everolimus (Afinitor)

Target: mTOR
FDA Approved Indication:
- Pancreatic, gastrointestinal, or lung origin neuroendocrine tumor
- Renal cell carcinoma
- Nonresectable subependymal giant cell astrocytoma associated with tuberous sclerosis
- Breast cancer (HR+, HER2-)

Gefitinib (Iressa)

Target: EGFR (HER1/ERBB1)
FDA Approved Indication:
- Non-small cell lung cancer (with EGFR exon 19 deletions or exon 21 substitution (L858R) mutations)

Ibrutinib (Imbruvica)

Target: BTK
FDA Approved Indication:
- Mantle cell lymphoma
- Chronic lymphocytic leukemia
- Waldenstrom's macroglobulinemia

Idelalisib (Zydelig)

Target: PI3Kδ
FDA Approved Indication:
- Chronic lymphocytic leukemia
- Follicular B-cell non-Hodgkin lymphoma
- Small lymphocytic lymphoma

Imatinib (Gleevec)

Target: KIT, PDGFR, ABL
FDA Approved Indication:
- GI stromal tumor (KIT+)
- Dermatofibrosarcoma protuberans
- Multiple hematologic malignancies including Philadelphia chromosome-positive ALL and CML

Ipilimumab (Yervoy)

Target: CTLA-4
FDA Approved Indication:
- Melanoma
- Renal cell carcinoma

Ixazomib (Ninlaro)

Target: Proteasome
FDA Approved Indication: Multiple Myeloma

Lapatinib (Tykerb)

Target: HER2 (ERBB2/neu), EGFR (HER1/ERBB1)
FDA Approved Indication:
- Breast cancer (HER2+)

Lenvatinib (Lenvima)

Target: VEGFR2
FDA Approved Indication:
- Renal cell carcinoma
- Thyroid cancer

Midostaurin (Rydapt)

Target: FLT3
FDA Approved Indication:
- acute myeloid leukemia (FLT3+)

Necitumumab (Portrazza)

Target: EGFR (HER1/ERBB1)
FDA Approved Indication:
- Squamous non-small cell lung cancer

Neratinib (Nerlynx)

Target: HER2 (ERBB2/neu)
FDA Approved Indication:
- Breast cancer (HER2 overexpressed/amplified)

Niraparib (Zejula)

Target: PARP
FDA Approved Indication:
- Ovarian cancer
- Fallopian tube cancer
- Peritoneal cancer

Nivolumab (Opdivo)

Target: PD-1
FDA Approved Indication:
- Colorectal cancer (dMMR and MSI-H)
- Head and neck squamous cell carcinoma
- Hepatocellular carcinoma
- Hodgkin lymphoma
- Melanoma
- Non-small cell lung cancer
- Renal cell carcinoma
- Urothelial carcinoma

Olaparib (Lynparza)

Target: PARP
FDA Approved Indication:
- Ovarian cancer (with BRCA mutation)

Olaratumab (Lartruvo)

Target: PDGFRα
FDA Approved Indication:
- Soft tissue sarcoma

Osimertinib (Tagrisso)

Target: EGFR
FDA Approved Indication:
- Non-small cell lung cancer (with EGFR T790M mutation)

Palbociclib (Ibrance)

Target: CDK4, CDK6
FDA Approved Indication:
- Breast cancer (HR+, HER2-)

Panitumumab (Vectibix)

Target: EGFR (HER1/ERBB1)
FDA Approved Indication:
- Colorectal cancer (KRAS wild type)

Pazopanib (Votrient)

Target: VEGFR, PDGFR, KIT
FDA Approved Indication:
- Renal cell carcinoma

Pembrolizumab (Keytruda)

Target: PD-1
FDA Approved Indication:
- Classical Hodgkin lymphoma
- Colorectal cancer (MSI-H/dMMR)
- Gastric cancer
- Melanoma
- Non-small cell lung cancer (PD-L1+)
- Head and neck squamous cell carcinoma
- Urothelial cancer
- Solid tumors (MSI-H/dMMR)

Pertuzumab (Perjeta)

Target: HER2 (ERBB2/neu)
FDA Approved Indication:
- Breast cancer (HER2+)

Ramucirumab (Cyramza)

Target: VEGFR2
FDA Approved Indications:
- Colorectal cancer
- Gastric cancer or Gastroesophageal junction (GEJ) adenocarcinoma
- Non-small cell lung cancer

Regorafenib (Stivarga)

Target: KIT, PDGFRβ, RAF, RET, VEGFR1/2/3
FDA Approved Indications:
- Colorectal cancer
- Gastrointestinal stromal tumors
- Hepatocellular carcinoma

Ribociclib (Kisqali)

Target: CDK4, CDK6
FDA Approved Indication:
- Breast cancer (HR+, HER2-)

Rucaparib (Rubraca)

Target: PARP
FDA Approved Indication:
- Ovarian cancer (with BRCA mutation)

Sipuleucel-T (Provenge)

FDA Approved Indication:
- Prostate cancer

Sonidegib (Odomzo)Smoothened

FDA Approved Indication:
- Basal cell carcinoma

Sorafenib (Nexavar)

Target: VEGFR, PDGFR, KIT, RAF
FDA Approved Indication:
- Hepatocellular carcinoma
- Renal cell carcinoma
- Thyroid carcinoma

Temsirolimus (Torisel)

Target: mTOR
FDA Approved Indication:
- Renal cell carcinoma

Trametinib (Mekinist)

Target: MEK
FDA Approved Indication:
- Melanoma (with BRAF V600 mutation)
- Non-small cell lung cancer (with BRAF V600E mutation)

Trastuzumab (Herceptin)

Target: HER2 (ERBB2/neu)
FDA Approved Indication:
- Breast cancer (HER2+)
- Gastric cancer (HER2+)

Vandetanib (Caprelsa)

Target: EGFR (HER1/ERBB1), RET, VEGFR2
FDA Approved Indication:
- Medullary thyroid cancer

Vemurafenib (Zelboraf)

Target: BRAF
FDA Approved Indication:
- Melanoma (with BRAF V600 mutation)

Vismodegib (Erivedge)

Target: PTCH, Smoothened
FDA Approved Indication:
- Basal cell carcinoma

Ziv-aflibercept (Zaltrap)

Target: PIGF, VEGFA/B
FDA Approved Indication:
- Colorectal cancer

DRUGS FOR LEUKEMIA AND LYMPHOMA

Rituximab (Rituxan, Mabthera)

Target: CD20
FDA Approved Indications:
- Non-Hodgkin’s lymphoma
- Chronic lymphocytic leukemia
- Rheumatoid arthritis
- Granulomatosis with polyangiitis

Rituximab/hyaluronidase human (Rituxan Hycela)

Target:CD20
FDA Approved Indications:
- Chronic lymphocytic leukemia
- Diffuse large B-cell lymphoma
- Follicular lymphoma

Romidepsin (Istodax)

Target: HDAC
FDA Approved Indication:
- Cutaneous T-cell lymphoma
- Peripheral T-cell lymphoma

Belinostat (Beleodaq)

Target: HDAC
FDA Approved Indication:
- Peripheral T-cell lymphoma

Ofatumumab (Arzerra, HuMax-CD20)

Target: CD20
FDA Approved Indication:
- Chronic lymphocytic leukemia

Blinatumomab (Blincyto)

Target: CD19/CD3
FDA Approved Indication:
- Acute lymphoblastic leukemia (precursor B-cell)

Nilotinib (Tasigna)

Target: ABL
FDA Approved Indication:
- Chronic myelogenous leukemia (Philadelphia chromosome positive)

Obinutuzumab (Gazyva)

Target: CD20
FDA Approved Indication:
- Chronic lymphocytic leukemia
- Follicular lymphoma

Dasatinib (Sprycel)

Target: ABL
FDA Approved Indication:
- Chronic myelogenous leukemia (Philadelphia chromosome positive)
- Acute lymphoblastic leukemia (Philadelphia chromosome positive)

Venetoclax (Venclexta)

Target: BCL2
FDA Approved Indication:
- Chronic lymphocytic leukemia (with 17p deletion)

Vorinostat (Zolinza)

Target: HDAC
FDA Approved Indication:
- Cutaneous T-cell lymphoma

Tositumomab (Bexxar)

Target: CD20
FDA Approved Indication:
- Non-Hodgkin's lymphoma

Siltuximab (Sylvant)

Target: IL-6
FDA Approved Indication:
- Multicentric Castleman's disease

Ruxolitinib (Jakafi)

Target: JAK1/2
FDA Approved Indication:
- Myelofibrosis

Alemtuzumab (Campath)

TARGET: CD52
FDA Approved Indication:
- B-cell chronic lymphocytic leukemia

Ponatinib (Iclusig)

Target: ABL, FGFR1-3, FLT3, VEGFR2
FDA Approved Indication:
- Chronic myelogenous leukemia
- Acute lymphoblastic leukemia (Philadelphia chromosome positive)

Panobinostat (Farydak)